Fortune Term Sheet· Bilin Lin·2026-10-25 20:05· 3 hours agoAI Score38

Haemanthus, Billy Evans' 'Theranos 2.0' Startup, Has Patents and $20M but No Product or CTO

Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product

AI Overview

Haemanthus, the Austin blood-testing startup run by Billy Evans, has raised as much as $20 million and holds at least one granted Raman spectroscopy patent.

Source:Fortune Term Sheet · fortune.com

Healthcare #Other #Healthcare #United States

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

Midu WeeklyMondays · funding trends and top roundsSee a sample issue →SF WeeklyFridays · San Francisco startups, rounds and eventsSee a sample issue →

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing